Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Faculty of Biology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Front Immunol. 2019 Apr 16;10:568. doi: 10.3389/fimmu.2019.00568. eCollection 2019.
Common variable immunodeficiency (CVID) is the most frequent symptomatic primary immunodeficiency. Patients with CVID are prone to recurrent bacterial infection due to the failure of adequate immunoglobulin production. Monogenetic defects have been identified in ~25% of CVID patients. Recently, mutations in , encoding the zinc-finger transcription factor IKAROS which is broadly expressed in hematopoietic cells, have been associated with a CVID-like phenotype. Herein we describe 11 patients with heterozygous variants from eight different families with autosomal dominant CVID and two siblings with an variant presenting with inflammatory bowel disease (IBD). This study shows that mutations affecting the DNA binding domain of IKAROS can impair the interaction with the target DNA sequence thereby preventing heterochromatin and pericentromeric localization (HC-PC) of the protein. Our results also indicate an impairment of pericentromeric localization of IKAROS by overexpression of a truncated variant, caused by an immature stop codon in . We also describe an additional variant in , encoding Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL), additionally presented in individuals of Family A. Our results indicate that this variant may impair the TRAIL-induced apoptosis in target cell lines and prohibit the NFκB activation by TRAIL and may act as a modifier in Family A.
普通变异性免疫缺陷症(CVID)是最常见的有症状原发性免疫缺陷症。由于免疫球蛋白产生不足,CVID 患者易发生反复细菌感染。约 25%的 CVID 患者存在单基因缺陷。最近,锌指转录因子 IKAROS 的编码基因( )突变与 CVID 样表型相关,该基因在造血细胞中广泛表达。本文描述了 8 个常染色体显性遗传 CVID 家系的 11 名杂合 变异患者和 2 名携带 变异的炎症性肠病(IBD)患者。本研究表明,影响 IKAROS DNA 结合域的突变可损害其与靶 DNA 序列的相互作用,从而阻止蛋白异染色质和着丝粒周围区(HC-PC)的定位。我们的结果还表明,由于 中不成熟的终止密码子,过表达截断变异体可导致 IKAROS 着丝粒周围定位受损。我们还描述了家族 A 中另一个编码肿瘤坏死因子相关凋亡诱导配体(TRAIL)的 变异。我们的结果表明,该变异可能会损害 TRAIL 诱导的靶细胞系凋亡,并阻止 TRAIL 诱导的 NFκB 激活,在家族 A 中可能作为修饰因子。